Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL

被引：14
|
作者：
Wierda, W [1 ]
Faderl, S [1 ]
O'Brien, S [1 ]
Cortes, J [1 ]
Ferrajoli, A [1 ]
Giles, F [1 ]
Andreff, M [1 ]
Koller, C [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.340.340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
340
引用
收藏
页码：101A / 101A
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of a modified fludarabine/cyclophosphamide combination in patients with relapsed/refractory CLL and LgNHL.
    Tuscano, J
    Lara, PN
    O'Donnell, RT
    Lauder, IL
    Wun, T
    BLOOD, 2001, 98 (11) : 294B - 294B
  • [22] Pharmacokinetics and response to treatment using a combination of fludarabine and alemtuzumab (FluCam) in patients with relapsed/refractory CLL.
    Elter, T.
    Kilp, J.
    Piironen, T.
    Borchmann, P.
    Schulz, H.
    Bohlius, J.
    Hallek, Michael J.
    Engert, Andreas
    BLOOD, 2006, 108 (11) : 336B - 336B
  • [23] A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2269 - 2273
  • [24] Subcutaneous alemtuzumab in patients with refractory/relapsed B-CLL after a fludarabine-based regimen.
    Bezares, R.
    Stemmelin, G.
    Argentieri, D.
    Lanari, E.
    Guy-Garay, E.
    Campestri, R.
    Bartomioli, M.
    Garcia, J.
    Giralt, S.
    Milone, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [25] Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH).
    Dufour, Annika
    Bohlander, S. K.
    Spiekermann, Karsten
    Schneider, Stephanie
    Braess, Jan
    Kakadiya, Purvi
    Mundt, Kirsten E.
    Smith, Helen
    Lin, Ming
    Barrett, Martin
    Hurst, Deborah
    Dmoszynska, Anna
    Bence-Bruckler, Isabelle
    Afanasiev, Boris V.
    Catalano, John
    Montillo, Marco
    Geisler, Christian H.
    Moiseev, Sergey I.
    Solal-Celigny, Philippe
    Robak, Tadeusz
    Hiddemann, Wolfgang
    BLOOD, 2010, 116 (21) : 598 - 598
  • [26] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    T Elter
    R James
    R Busch
    D Winkler
    M Ritgen
    S Böttcher
    C Kahl
    W Gassmann
    M Stauch
    I Hasan
    P Staib
    K Fischer
    A-M Fink
    J Bahlo
    A Bühler
    H Döhner
    C-M Wendtner
    S Stilgenbauer
    A Engert
    M Hallek
    Leukemia, 2012, 26 : 2549 - 2552
  • [27] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    Elter, T.
    James, R.
    Busch, R.
    Winkler, D.
    Ritgen, M.
    Boettcher, S.
    Kahl, C.
    Gassmann, W.
    Stauch, M.
    Hasan, I.
    Staib, P.
    Fischer, K.
    Fink, A-M
    Bahlo, J.
    Buehler, A.
    Doehner, H.
    Wendtner, C-M
    Stilgenbauer, S.
    Engert, A.
    Hallek, M.
    LEUKEMIA, 2012, 26 (12) : 2549 - 2552
  • [28] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2011, 118 (21) : 1669 - 1669
  • [29] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [30] Outpatient-based therapy with oral fludarabine and alemtuzumab for Asian patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
    Hwang, William
    Dearden, C.
    Loh, S. M.
    Linn, Y. C.
    Tien, S. L.
    Teoh, G.
    Lim, L. F.
    Liew, P. X.
    How, G. F.
    Heng, K. K.
    Goh, Y. T.
    Lee, L. H.
    BLOOD, 2006, 108 (11) : 336B - 337B
12345